Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

bioAffinity Technologies (BIAF) EBT (2022 - 2025)

bioAffinity Technologies (BIAF) has disclosed EBT for 4 consecutive years, with -$3.1 million as the latest value for Q4 2025.

  • Quarterly EBT fell 5.64% to -$3.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$14.9 million through Dec 2025, down 64.66% year-over-year, with the annual reading at -$14.9 million for FY2025, 64.66% down from the prior year.
  • EBT for Q4 2025 was -$3.1 million at bioAffinity Technologies, up from -$5.0 million in the prior quarter.
  • The five-year high for EBT was -$88052.0 in Q2 2022, with the low at -$5.0 million in Q3 2025.
  • Average EBT over 4 years is -$2.5 million, with a median of -$2.2 million recorded in 2023.
  • Peak annual rise in EBT hit 53.48% in 2023, while the deepest fall reached 1871.09% in 2023.
  • Over 4 years, EBT stood at -$1.7 million in 2022, then crashed by 41.58% to -$2.4 million in 2023, then decreased by 25.14% to -$3.0 million in 2024, then fell by 5.64% to -$3.1 million in 2025.
  • According to Business Quant data, EBT over the past three periods came in at -$3.1 million, -$5.0 million, and -$4.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.